Use of teriparatide to accelerate the healing of lower extremity stress fractures in high-level and high-performance athletes: a phase IV/II multicenter randomized clinical trial

Stress fractures (SFX) are a major problem for athletes, because they need to be a relatively long period of time away from activity. Most SFX are treated conservatively, and in some cases may result in delayed union or nonunion. To date, there is not any medication approved to accelerate the healin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Oliveras Font, Mercè
Format: Dissertation
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Oliveras Font, Mercè
description Stress fractures (SFX) are a major problem for athletes, because they need to be a relatively long period of time away from activity. Most SFX are treated conservatively, and in some cases may result in delayed union or nonunion. To date, there is not any medication approved to accelerate the healing of SFX. Recently, teriparatide, an anabolic agent used in the treatment of osteoporosis, has shown as a promising treatment to accelerate the healing of fractures, by increasing bone formation. Objectives: To evaluate the efficacy and safety of 20 μg and 40 μg of teriparatide compared with placebo, for treating lower extremity SFX in high-level and high-performance athletes. Efficacy endpoints will be the time to radiographic healing and the return to sport time, measured in weeksDesign: A phase IV/II, multicenter, randomized, double-blind, placebo-controlled clinical trialSetting: Hospital Universitari Doctor Josep Trueta and five Sports Medicine Centers of CatalunyaParticipants: High-level and high-performance athletes diagnosed with lower extremity stress fractures. Intervention: Teriparatide 20 μg (n=46), teriparatide 40 μg (n=46) and placebo (n=46), all as a daily subcutaneous injection for 8 weeks
format Dissertation
fullrecord <record><control><sourceid>csuc_XX2</sourceid><recordid>TN_cdi_csuc_recercat_oai_recercat_cat_2072_254711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_recercat_cat_2072_254711</sourcerecordid><originalsourceid>FETCH-csuc_recercat_oai_recercat_cat_2072_2547113</originalsourceid><addsrcrecordid>eNqdjs1KxEAQhHPxIOo79Assmqgs7HVZMXf1GppOZadhMhN6Ov49lk_oLArePRRdH3RRdd58PRdQnshhurCx6wjyTCyCiMqVAiiAo6bj6TPmNxjh3Q2z-geVakqhyVh8rZY0UdBj2ES8IhKn8QcX2JRt5iQg9hDhKDtiWgLXCf3Ldd_TvEZXQapryGoyz_qJkaR2q3AkN-V42ZxNHAuufu9F0z4cnvaPGymrDAaBCfuQWf_gpO5m2w3d_d22bW__k_kG2nto_g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>dissertation</recordtype></control><display><type>dissertation</type><title>Use of teriparatide to accelerate the healing of lower extremity stress fractures in high-level and high-performance athletes: a phase IV/II multicenter randomized clinical trial</title><source>Recercat</source><creator>Oliveras Font, Mercè</creator><creatorcontrib>Oliveras Font, Mercè</creatorcontrib><description>Stress fractures (SFX) are a major problem for athletes, because they need to be a relatively long period of time away from activity. Most SFX are treated conservatively, and in some cases may result in delayed union or nonunion. To date, there is not any medication approved to accelerate the healing of SFX. Recently, teriparatide, an anabolic agent used in the treatment of osteoporosis, has shown as a promising treatment to accelerate the healing of fractures, by increasing bone formation. Objectives: To evaluate the efficacy and safety of 20 μg and 40 μg of teriparatide compared with placebo, for treating lower extremity SFX in high-level and high-performance athletes. Efficacy endpoints will be the time to radiographic healing and the return to sport time, measured in weeksDesign: A phase IV/II, multicenter, randomized, double-blind, placebo-controlled clinical trialSetting: Hospital Universitari Doctor Josep Trueta and five Sports Medicine Centers of CatalunyaParticipants: High-level and high-performance athletes diagnosed with lower extremity stress fractures. Intervention: Teriparatide 20 μg (n=46), teriparatide 40 μg (n=46) and placebo (n=46), all as a daily subcutaneous injection for 8 weeks</description><language>eng</language><publisher>Facultat de Medicina</publisher><subject>Athletes ; Cames ; Esportistes ; Ferides i lesions ; Fractures ; Leg ; Medicina esportiva ; Sports medicine ; Wounds and injuries</subject><creationdate>2015</creationdate><rights>Attribution-NonCommercial-NoDerivs 3.0 Spain &lt;a href="http://creativecommons.org/licenses/by-nc-nd/3.0/es/"&gt;http://creativecommons.org/licenses/by-nc-nd/3.0/es/&lt;/a&gt;</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,311,780,885,26974</link.rule.ids><linktorsrc>$$Uhttps://recercat.cat/handle/2072/254711$$EView_record_in_Consorci_de_Serveis_Universitaris_de_Catalunya_(CSUC)$$FView_record_in_$$GConsorci_de_Serveis_Universitaris_de_Catalunya_(CSUC)$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Oliveras Font, Mercè</creatorcontrib><title>Use of teriparatide to accelerate the healing of lower extremity stress fractures in high-level and high-performance athletes: a phase IV/II multicenter randomized clinical trial</title><description>Stress fractures (SFX) are a major problem for athletes, because they need to be a relatively long period of time away from activity. Most SFX are treated conservatively, and in some cases may result in delayed union or nonunion. To date, there is not any medication approved to accelerate the healing of SFX. Recently, teriparatide, an anabolic agent used in the treatment of osteoporosis, has shown as a promising treatment to accelerate the healing of fractures, by increasing bone formation. Objectives: To evaluate the efficacy and safety of 20 μg and 40 μg of teriparatide compared with placebo, for treating lower extremity SFX in high-level and high-performance athletes. Efficacy endpoints will be the time to radiographic healing and the return to sport time, measured in weeksDesign: A phase IV/II, multicenter, randomized, double-blind, placebo-controlled clinical trialSetting: Hospital Universitari Doctor Josep Trueta and five Sports Medicine Centers of CatalunyaParticipants: High-level and high-performance athletes diagnosed with lower extremity stress fractures. Intervention: Teriparatide 20 μg (n=46), teriparatide 40 μg (n=46) and placebo (n=46), all as a daily subcutaneous injection for 8 weeks</description><subject>Athletes</subject><subject>Cames</subject><subject>Esportistes</subject><subject>Ferides i lesions</subject><subject>Fractures</subject><subject>Leg</subject><subject>Medicina esportiva</subject><subject>Sports medicine</subject><subject>Wounds and injuries</subject><fulltext>true</fulltext><rsrctype>dissertation</rsrctype><creationdate>2015</creationdate><recordtype>dissertation</recordtype><sourceid>XX2</sourceid><recordid>eNqdjs1KxEAQhHPxIOo79Assmqgs7HVZMXf1GppOZadhMhN6Ov49lk_oLArePRRdH3RRdd58PRdQnshhurCx6wjyTCyCiMqVAiiAo6bj6TPmNxjh3Q2z-geVakqhyVh8rZY0UdBj2ES8IhKn8QcX2JRt5iQg9hDhKDtiWgLXCf3Ldd_TvEZXQapryGoyz_qJkaR2q3AkN-V42ZxNHAuufu9F0z4cnvaPGymrDAaBCfuQWf_gpO5m2w3d_d22bW__k_kG2nto_g</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Oliveras Font, Mercè</creator><general>Facultat de Medicina</general><scope>XX2</scope></search><sort><creationdate>201501</creationdate><title>Use of teriparatide to accelerate the healing of lower extremity stress fractures in high-level and high-performance athletes: a phase IV/II multicenter randomized clinical trial</title><author>Oliveras Font, Mercè</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-csuc_recercat_oai_recercat_cat_2072_2547113</frbrgroupid><rsrctype>dissertations</rsrctype><prefilter>dissertations</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Athletes</topic><topic>Cames</topic><topic>Esportistes</topic><topic>Ferides i lesions</topic><topic>Fractures</topic><topic>Leg</topic><topic>Medicina esportiva</topic><topic>Sports medicine</topic><topic>Wounds and injuries</topic><toplevel>online_resources</toplevel><creatorcontrib>Oliveras Font, Mercè</creatorcontrib><collection>Recercat</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Oliveras Font, Mercè</au><format>dissertation</format><genre>dissertation</genre><ristype>THES</ristype><btitle>Use of teriparatide to accelerate the healing of lower extremity stress fractures in high-level and high-performance athletes: a phase IV/II multicenter randomized clinical trial</btitle><date>2015-01</date><risdate>2015</risdate><abstract>Stress fractures (SFX) are a major problem for athletes, because they need to be a relatively long period of time away from activity. Most SFX are treated conservatively, and in some cases may result in delayed union or nonunion. To date, there is not any medication approved to accelerate the healing of SFX. Recently, teriparatide, an anabolic agent used in the treatment of osteoporosis, has shown as a promising treatment to accelerate the healing of fractures, by increasing bone formation. Objectives: To evaluate the efficacy and safety of 20 μg and 40 μg of teriparatide compared with placebo, for treating lower extremity SFX in high-level and high-performance athletes. Efficacy endpoints will be the time to radiographic healing and the return to sport time, measured in weeksDesign: A phase IV/II, multicenter, randomized, double-blind, placebo-controlled clinical trialSetting: Hospital Universitari Doctor Josep Trueta and five Sports Medicine Centers of CatalunyaParticipants: High-level and high-performance athletes diagnosed with lower extremity stress fractures. Intervention: Teriparatide 20 μg (n=46), teriparatide 40 μg (n=46) and placebo (n=46), all as a daily subcutaneous injection for 8 weeks</abstract><pub>Facultat de Medicina</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_csuc_recercat_oai_recercat_cat_2072_254711
source Recercat
subjects Athletes
Cames
Esportistes
Ferides i lesions
Fractures
Leg
Medicina esportiva
Sports medicine
Wounds and injuries
title Use of teriparatide to accelerate the healing of lower extremity stress fractures in high-level and high-performance athletes: a phase IV/II multicenter randomized clinical trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A31%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-csuc_XX2&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&rft.genre=dissertation&rft.btitle=Use%20of%20teriparatide%20to%20accelerate%20the%20healing%20of%20lower%20extremity%20stress%20fractures%20in%20high-level%20and%20high-performance%20athletes:%20a%20phase%20IV/II%20multicenter%20randomized%20clinical%20trial&rft.au=Oliveras%20Font,%20Merc%C3%A8&rft.date=2015-01&rft_id=info:doi/&rft_dat=%3Ccsuc_XX2%3Eoai_recercat_cat_2072_254711%3C/csuc_XX2%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true